Not Yet RecruitingNCT07249554
Testing medicines for alcohol use during inpatient care
Medication studyAges 21–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
- Listed locations
- Havre de GraceSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: November 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 45
- Sponsor
- Johns Hopkins University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT07249554
- Official title
Show the full official title
Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Havre de Grace
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Johns Hopkins University, a university.
Does this study involve medication?
Yes. The study involves medication, including Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1) and Naltrexone (oral tablets).
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
